重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2026年1月7日 (二)股东会召开的地点：武汉市汉阳区龙兴西街5号九州通总部大厦会议室 证券代码：600998 证券简称：九州通 公告编号：临2026-004 九州通医药集团股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，采用现场投票和网络投票相结合的方式进行表决，经推举，会议由副董 事长刘兆年先生主持。会议召集、召开和表决程序符合《公司法》及《公司章程》的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事14人，列席14人； 2、公司董事会秘书出席了本次会议；部分高级管理人员列席了本次会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：关于2026年度公司及下属企业申请银行等机构综合授信 ...

证券日报网讯 1月7日，九州通发布公告称，公司2026年第一次临时股东会审议通过《关于2026年度公 司及下属企业申请银行等机构综合授信计划的议案》《关于2026年度公司及下属企业办理银行等机构综 合授信及其他业务提供担保的议案》《关于公司2026年度使用临时闲置资金委托理财预计的议案》等多 项议案。 （文章来源：证券日报） ...

证券日报网讯1月7日，国科恒泰（301370）发布公告称，公司将于2026年1月26日召开2026年第一次临 时股东会。 ...

Core Insights - The article highlights that Luyan Pharmaceutical (002788) has added the "Brain Engineering" concept due to its transaction records with the distributor of Borui Kang, which is the first company in China to complete clinical trials for minimally invasive brain-machine interfaces [1] Company Overview - Luyan Pharmaceutical's main business includes the distribution of pharmaceuticals, traditional Chinese medicine pieces, medical devices, and vaccines, as well as retail pharmacy chains [1] Financial Performance - For the first three quarters of 2025, Luyan Pharmaceutical reported a main revenue of 15.855 billion yuan, an increase of 2.87% year-on-year [1] - The net profit attributable to shareholders was 220 million yuan, a decrease of 14.64% year-on-year [1] - The net profit after deducting non-recurring items was also 220 million yuan, down 15.14% year-on-year [1] - In the third quarter of 2025, the company achieved a single-quarter main revenue of 5.455 billion yuan, up 6.81% year-on-year [1] - The single-quarter net profit attributable to shareholders was 65.1366 million yuan, a decline of 2.74% year-on-year [1] - The single-quarter net profit after deducting non-recurring items was 66.6689 million yuan, down 7.93% year-on-year [1] - The company's debt ratio stands at 74.98%, with investment income reported at -10.8849 million yuan and financial expenses at 139 million yuan, while the gross profit margin is 6.96% [1]

Group 1 - The company emphasizes the importance of new technologies such as artificial intelligence and big data in the fields of healthcare and pharmaceuticals, and is conducting related research and exploration [2] - The company has not developed or applied the "Luyan-Alibaba Health AI Diagnosis Assistant" as of now [2] - Investors are advised to refer to the company's official announcements for accurate information [2]

嘉事堂公告称，公司股票在2026年1月5 - 7日连续三个交易日内，日收盘价格涨幅累计偏离29.61%，属 股票交易异常波动。公司核查后表示，前期披露信息无需更正补充，未发现公共传媒报道可能影响股价 的未公开信息，近期经营及内外部环境无重大变化，公司、控股股东和实控人无应披露未披露重大事 项，异常波动期间控股股东和实控人无买卖公司股票行为。公司提醒投资者以指定媒体信息为准，理性 投资。 ...

华润医药商业集团相关负责人表示，鲁南制药集团的创新活力与华润医药商业集团的渠道优势完美互 补，此次合作是双方"以实力筑基、以创新破局"的战略选择。面对医药行业转型升级的挑战，双方需 以"资源通融、模式共生"为核心，通过数字化赋能与全渠道协同，探索"工商深度联动"的新范式。未 来，希望双方合力打造"韧性更强、价值更高、影响更远"的战略合作伙伴关系，共同为健康中国建设注 入持久动力。 会上，鲁南制药集团相关负责人表示，此次与华润医药商业集团达成战略合作，是鲁南制药集团在"健 康中国"战略指引下，积极构建现代化医药产业新生态的重要举措。未来，期待通过本次战略协同与"长 赢计划"在各区域的扎实落地，双方以"长远共赢"为核心理念，聚焦产品供应链优化、市场服务深化与 创新模式探索，推动医药产业资源优化配置，以数字化、国际化赋能产业升级，共同探索健康产业可持 续发展路径，为全民健康保驾护航。 1月6日，鲁南制药集团党委书记、董事长、总经理张贵民会见华润医药商业集团一行，并作专题授课， 双方举行战略合作签约仪式。 张贵民以《生命的中医药思考》为题，从中医药文化的哲学根基出发，结合现代生命科学与健康需求， 系统阐释了中医药在维 ...

Core Viewpoint - The company emphasizes the importance of new technologies such as artificial intelligence and big data in the medical and pharmaceutical fields, indicating ongoing research and exploration in these areas [1] Group 1 - The company has not yet developed or applied the "Luyan-Ali Health AI Diagnosis Assistant" [1]

Company News - China Pharmaceutical plans to acquire 70% stake in Shanghai Zezheng Pharmaceutical for 525 million yuan, aiming to enhance its comprehensive strength in pharmaceutical R&D innovation [3] - Lens Technology is a strategic investor in Strong Brain Technology, exclusively undertaking the mass production of its core hardware modules [3] - Shengyang Co. intends to acquire 51% stake in Shenzhen Daren Gaoke Electronics for 74.47 million yuan to expand its energy storage BMS layout [4] - Zijin Mining's stock price has risen for four consecutive days due to the increase in non-ferrous metal prices and expected earnings growth in 2025, with its market value surpassing 1 trillion yuan for the first time [4] - Chuangyuan Xinke's merger and acquisition materials have been officially accepted by the Beijing Stock Exchange, with plans to acquire 100% stake in Weiyu Tiandao [4] Industry News - Multiple commercial aerospace concept stocks, including China Satellite and Aerospace Electronics, have issued announcements warning about speculative risks [3] - The Ministry of Water Resources has called for accelerated construction of a modern water network by 2026 to solidify the water conservancy foundation for agricultural and rural modernization [2]

Market Performance - The pharmaceutical commercial sector increased by 0.97% compared to the previous trading day, with Luyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Key stocks in the pharmaceutical commercial sector showed significant gains, with Yinghe Pharmaceutical rising by 10.02% to a closing price of 22.72, and Jiashitang also increasing by 10.00% to 17.38 [1] - Other notable performers included Saili Medical and Renmin Tongtai, both showing increases of 10.00% and 2.64% respectively [1] Trading Volume and Value - Yinghe Pharmaceutical had a trading volume of 636,200 shares, resulting in a transaction value of approximately 1.396 billion yuan [1] - Jiashitang and Saili Medical also reported substantial trading volumes of 119,600 and 74,200 shares, with transaction values of around 208 million yuan and 185 million yuan respectively [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 188 million yuan from institutional investors and 252 million yuan from speculative funds, while retail investors saw a net inflow of 439 million yuan [2] - The capital flow data indicates varying investor sentiment, with retail investors showing a positive trend in the sector [2] Stock-Specific Capital Flow - Luyuan Pharmaceutical had a net inflow from retail investors of approximately 1.02 billion yuan, despite a net outflow from institutional and speculative investors [3] - Jiashitang and Saili Medical also experienced mixed capital flows, with Jiashitang seeing a net inflow of 84.96 million yuan from institutional investors [3]